Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Secukinumab
Secukinumab/kg · 1 trial · 1 indication
Corneal staining was done with 2% sodium fluorescein instilled into the lower palpebral conjunctiva of each eye. Staining was assessed in 5 zones of the cornea (central plus 4 quadrants) and rated on a scale of 0 (no staining) to 3 (severe, confluent staining). A mean of the 5 zones for the study eye was calculated. A higher score indicates a drier eye. A negative change score indicates improvement in dryness.
| Arm | Type | Description |
|---|---|---|
| Secukinumab 10 mg/kg | EXPERIMENTAL | Patients received a single dose of secukinumab 10 mg/kg infused intravenously over a 2 hour period. |
| Canakinumab 10 mg/kg | EXPERIMENTAL | Patients received a single dose of canakinumab 10 mg/kg infused intravenously over a 2 hour period. |
| Placebo | PLACEBO_COMPARATOR | Patients received a single placebo infusion intravenously over a 2 hour period. |
| Name | Type | Description |
|---|---|---|
| Secukinumab 10 mg/kg | BIOLOGICAL | Secukinumab was prepared in a sterile water solution. |
| Canakinumab 10 mg/kg | BIOLOGICAL | Canakinumab was prepared in a sterile water solution. |
| Placebo | BIOLOGICAL | The placebo solution for infusion contained 5% glucose. |
Inclusion Criteria: * Male and female patients age 18-85 with a diagnosis of moderate to severe dry eye. * Schirmer test without anesthesia ≥ 1 and \< 10 mm wetting over 5 minutes in at least 1 eye. * Tear break up time \< 7 seconds in at least 1 eye. * Corneal staining score ≥ 3 (National Eye Inst...
Secukinumab is used for chronic plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, ankylosing spondylitis, and moderate to severe chronic plaque-type psoriasis. It is being studied in clinical trials for these conditions, including active psoriatic arthritis with axial skeleton involvement.
Secukinumab is a monoclonal antibody, indicated by its -mab suffix. It is being developed for immunology indications, including psoriatic arthritis and giant cell arteritis, and is in Phase 3 clinical trials for several of these conditions.
Secukinumab is developed by Novartis AG, which trades on the New York Stock Exchange under the ticker NVS. The company is conducting clinical trials of Secukinumab across multiple countries, including the United States, Germany, and the United Kingdom.
Secukinumab is in Phase 3 clinical development for conditions such as axial psoriatic arthritis and giant cell arteritis. It has also completed Phase 1 and Phase 2 trials. Secukinumab is an investigational drug and is not approved for the indications being studied.
Secukinumab has been studied in clinical trials including NCT02721966 for active psoriatic arthritis with axial skeleton involvement, NCT03765788 for giant cell arteritis, NCT05380453 for new onset giant cell arteritis, and NCT06130540 for giant cell arteritis or polymyalgia rheumatica.
Secukinumab is the generic name for the drug also known as Cosentyx. It is a monoclonal antibody developed by Novartis AG for immunology indications such as psoriasis and psoriatic arthritis.